Therapeutic Area | MeSH |
---|---|
mental disorders | D001523 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ABILIFY ASIMTUFII | Otsuka | N-217006 RX | 2023-04-27 | 2 products, RLD, RS |
ABILIFY | Otsuka | N-021436 RX | 2002-11-15 | 6 products, RLD |
ABILIFY MAINTENA KIT | Otsuka | N-202971 RX | 2013-02-28 | 4 products, RLD, RS |
OPIPZA | Xiamen LP Pharmaceutical | N-216655 RX | 2024-07-22 | 3 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
abilify | New Drug Application | 2025-01-29 |
abilify abilify | New Drug Application | 2013-08-13 |
abilify abilify discmelt | 2008-08-28 | |
abilify asimtufii | New Drug Application | 2025-01-29 |
abilify maintena | New Drug Application | 2025-03-05 |
abilify maintena kit | New Drug Application | 2013-04-02 |
abilify mycite | New Drug Application | 2025-01-31 |
aripiprazole | ANDA | 2025-03-24 |
aripiprazole oral solution | ANDA | 2016-08-31 |
aristada | New Drug Application | 2025-01-28 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
schizophrenia | EFO_0000692 | D012559 | F20 |
schizophrenia spectrum and other psychotic disorders | — | D019967 | — |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Aripiprazole, Abilify Maintena Kit, Otsuka Pharm Co Ltd | |||
11648347 | 2034-04-06 | DP | |
10525057 | 2034-03-08 | U-543, U-1632, U-2723 | |
10980803 | 2033-09-24 | U-543, U-1632 | |
11154553 | 2033-09-24 | U-814, U-1632, U-3245 | |
11344547 | 2033-09-24 | U-814, U-1632, U-3245 | |
11400087 | 2033-09-24 | U-814, U-1632, U-3245 | |
7807680 | 2024-10-19 | DP | |
8030313 | 2024-10-19 | U-543, U-1632 | |
8722679 | 2024-10-19 | DP | |
Aripiprazole, Abilify Mycite Kit, Otsuka | |||
9268909 | 2033-10-15 | DP | U-2168 |
10517507 | 2032-06-13 | DP | |
9320455 | 2031-12-15 | DP | |
11229378 | 2031-07-11 | DP | |
8547248 | 2030-12-18 | DP | U-2167 |
8258962 | 2030-11-25 | DP | |
8961412 | 2030-11-17 | DP | |
9941931 | 2030-11-04 | DP | |
11464423 | 2030-09-15 | DP | |
8114021 | 2030-06-21 | DP | |
8545402 | 2030-04-27 | DP | |
8847766 | 2030-03-29 | DP | U-2167 |
9149577 | 2029-12-15 | DP | |
8718193 | 2029-12-05 | DP | |
9433371 | 2029-09-15 | DP | |
8945005 | 2029-08-19 | DP | U-2167 |
10441194 | 2029-07-26 | DP | |
8956288 | 2029-07-06 | DP | U-2167 |
8674825 | 2029-04-09 | DP | U-2170 |
9060708 | 2029-03-05 | DP | |
9258035 | 2029-03-05 | DP | |
9119554 | 2028-12-16 | DP | |
9444503 | 2027-11-19 | DP | U-2169 |
7978064 | 2026-09-14 | DP | |
11476952 | 2026-04-28 | DP | |
Aripiprazole, Abilify Asimtufii, Otsuka | |||
10517951 | 2033-04-23 | DP | U-814, U-3245 |
11097007 | 2033-04-23 | DP | U-814, U-3245 |
11638757 | 2033-04-23 | DP | U-814, U-3245 |
8399469 | 2025-06-29 | DP | |
8338427 | 2025-03-15 | DP | U-543, U-1530, U-1633 |
8338428 | 2023-08-06 | DP | U-543, U-1530, U-1633 |
8759351 | 2023-08-06 | DP | U-1530, U-1633 |
Aripiprazole, Abilify, Otsuka | |||
8759350 | 2027-03-02 | U-1529 | |
9125939 | 2026-07-28 | U-1749 | |
7115587 | 2024-07-21 | DP | U-764 |
7550445 | 2024-07-21 | DP | |
8017615 | 2024-06-16 | DP | |
9387182 | 2023-12-25 | U-1529 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | — | 1 | 1 | 2 |
Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 1 | 1 |
Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Aripiprazole |
INN | aripiprazole |
Description | Aripiprazole is an N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. It has a role as a H1-receptor antagonist, a serotonergic agonist, a second generation antipsychotic and a drug metabolite. It is a quinolone, a N-arylpiperazine, a N-alkylpiperazine, a dichlorobenzene, an aromatic ether and a delta-lactam. |
Classification | Small molecule |
Drug class | antiulcer agents (benzimidazole derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1 |
PDB | — |
CAS-ID | 129722-12-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1112 |
ChEBI ID | 31236 |
PubChem CID | 60795 |
DrugBank | DB01238 |
UNII ID | 82VFR53I78 (ChemIDplus, GSRS) |